EV-101: A Phase I Study of Single-Agent Enfortumab Vedotin in Patients With Nectin-4–Positive Solid Tumors, Including Metastatic Urothelial Carcinoma

PURPOSE: To assess the safety/tolerability and antitumor activity of enfortumab vedotin (EV), a novel investigational antibody-drug conjugate that delivers the microtubule-disrupting agent, monomethyl auristatin E, to cells that express Nectin-4. METHODS: EV-101 is a phase I dose escalation/expansio...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Clin Oncol
Autori principali: Rosenberg, Jonathan, Sridhar, Srikala S., Zhang, Jingsong, Smith, David, Ruether, Dean, Flaig, Thomas W., Baranda, Joaquina, Lang, Joshua, Plimack, Elizabeth R., Sangha, Randeep, Heath, Elisabeth I., Merchan, Jamie, Quinn, David I., Srinivas, Sandy, Milowsky, Matthew, Wu, Chunzhang, Gartner, Elaina M., Zuo, Peiying, Melhem-Bertrandt, Amal, Petrylak, Daniel P.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society of Clinical Oncology 2020
Soggetti:
ORIGINAL REPORTS
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7106979/
https://ncbi.nlm.nih.gov/pubmed/32031899
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.19.02044
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi